A Tool to Predict Risk for Gastric Cancer in Patients With Peptic Ulcer Disease on the Basis of a Nationwide Cohort

Lee, Teng‐Yu; Wang, Chang-Bi; Chen, Tzu-Ting; Kuo, Ken N.; Wu, Ming–Shiang; Lin, Jaw–Town; Wu, Chunying; Wu, Cheng‐Yi; Chen, Ching-Chow; Lin, Chun‐Hung; Chow, Lu‐Ping; Chen, Chieh‐Chang; Jyh-Ming, Liou

doi:10.1016/j.cgh.2014.07.043

Cited by 27 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…developed a prognostic model based on a large cohort population to assess the impact of lifestyle factors on the risk of occurrence of gastric cancer; Lee et al . proposed a prognostic tool aimed at predicting cumulative incidence of gastric cancer in patients with peptic ulcer, while Tata et al . developed a diagnostic scoring system based on clinical variables .…”

mentioning

confidence: 99%

Prediction of the 10‐year probability of gastric cancer occurrence in the Japanese population: the JPHC study cohort II

Charvat¹,

Sasazuki²,

Inoue

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

Gastric cancer is a particularly important issue in Japan, where incidence rates are among the highest observed. In this work, we provide a risk prediction model allowing the estimation of the 10-year cumulative probability of gastric cancer occurrence. The study population consisted of 19,028 individuals from the Japanese Public Health Center cohort II who were followed-up from 1993 to 2009. A parametric survival model was used to assess the impact on the probability of gastric cancer of clinical and lifestyle-related risk factors in combination with serum anti-Helicobacter pylori antibody titres and pepsinogen I and pepsinogen II levels. Based on the resulting model, cumulative probability estimates were calculated and a simple risk scoring system was developed. A total of 412 cases of gastric cancer occurred during 270,854 person-years of follow-up. The final model included (besides the biological markers) age, gender, smoking status, family history of gastric cancer and consumption of highly salted food. The developed prediction model showed good predictive performance in terms of discrimination (optimism-corrected c-index: 0. pylori might be almost a necessary condition for gastric cancer development and that negativity of H. pylori infection in gastric cancer cases reflects the inability of the bacteria to develop on the mucosa of patients with severe atrophic

show abstract

mentioning

confidence: 99%

Prediction of the 10‐year probability of gastric cancer occurrence in the Japanese population: the JPHC study cohort II

Charvat¹,

Sasazuki²,

Inoue

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…The NHIRD comprises comprehensive information, including demographic data, dates of clinical visits, diagnostic codes, operation codes, and details of prescriptions, among others, as described in our previous studies. (18,23,(26)(27)(28)(29)(30) This study has been approved by the research ethics committee of the National Health Research Institutes in Taiwan.…”

Section: Methodsmentioning

confidence: 99%

Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus–related hepatocellular carcinoma after radiofrequency ablation

et al. 2015

Self Cite

View full text Add to dashboard Cite

Radiofrequency ablation (RFA) is the best choice for curative treatment of hepatocellular carcinoma (HCC) cases not suitable for surgical intervention, but efforts should be made to reduce the risk of tumor recurrence. We aimed to investigate the association between nucleos(t)ide analog (NA) therapy for hepatitis B virus (HBV) and the risk of HCC recurrence post-RFA. Using the Taiwan National Health Insurance Research Database between July 1, 2004 and December 31, 2012, we screened 48,807 patients with newly diagnosed HBV-related HCC. We identified 850 patients (200 patients who used NAs for more than 90 days and 650 who never used NA post-RFA) who received RFA as a potentially curative treatment for HCC. Patients in the NA-treated cohort were randomly matched 1:2 with patients in the untreated cohort by age, sex, cirrhosis, and the time period between RFA and initiation of NA therapy. Finally, 133 patients were recruited in the NA-treated group and 266 in the untreated group for analysis. Cumulative incidences of and hazard ratios (HRs) for HCC recurrence were analyzed after adjusting for competing mortality. The HCC recurrence rate of the NA-treated group was significantly lower than that of the untreated group (2-year recurrence rate: 41.8%; 95% confidence interval [CI]: 32.9-50.6 vs. 54.3%; 95% CI: 48.0-60.6; modified log-rank test: P < 0.05). In modified Cox's regression analysis, NA therapy was independently associated with a decreased risk of HCC recurrence (HR, 0.69; 95% CI: 0.50-0.95; P < 0.05). Multivariate stratified analyses verified the association of NA therapy and decreased HCC recurrence in almost all patient subgroups. Conclusion: NA therapy was associated with a decreased risk of HCC recurrence among patients with HBV-related HCC post-RFA. (HEPATOLOGY 2016;63:1517-1527 SEE EDITORIAL ON PAGE 1415H epatocellular carcinoma (HCC) remains the third-most common cause of cancer death worldwide, and HCC-related deaths have been estimated to be approximately 700,000 per year.(1) With a low survival rate of less than 12% in 5 years, HCC is the fastest rising cause of cancer death in the United States.(2) Although HCC surveillance for high-risk populations may contribute to early tumor treatment and reduced mortality rates,the clinical outcomes of patients receiving curative

show abstract

“…GC is still the second most frequent cause of cancer death in the world [2,3]. Gastroduodenal ulcers are regarded as a risk factor for GC, and approximately 2% of patients with GC showed evidence of GU [4,5]. It has been suggested that both genetic and environmental factors play a role in the causation of GC and gastroduodenal diseases.…”

Section: Introductionmentioning

confidence: 99%

No Evidence for an Association between JC Polyomavirus Infection and Gastroduodenal Diseases

Cherati

Yahyapour

Ranaee

et al. 2018

Gastrointest Tumors

View full text Add to dashboard Cite

Background: Helicobacter pylori (HP) infection is one of the hypothesized infectious etiologies of gastric cancer (GC) and other gastroduodenal diseases. It was suggested that other infectious agents, including oncogenic viruses, may increase the risk of gastroduodenal diseases. A number of reports regarding JC polyomavirus (JCPyV) have shown that JCPyV could be implicated in colorectal cancer and gastrointestinal carcinogenesis. Objective: The current investigation aimed to investigate whether JCPyV could have any association with the pathogenesis of gastroduodenal diseases either alone or together with HP. Methods: A total of 237 fresh or formalin-fixed and paraffin-embedded gastroduodenal samples were examined by quantitative real-time polymerase chain reaction targeting the JCPyV large tumor antigen (LTag) oncogene, and viral load was determined as viral copy number/cell. Results: In total, 2 out of 237 samples (0.8%) were positive for JCPyV LTag DNA. One positive sample derived from diffuse-type gastric adenocarcinoma (6.8 × 10^–3 copies/cell) and other JCPyV-positive sample obtained from a patient with gastritis (2.5 × 10^–3 copies/cell) were recorded. Both JCPyV-positive samples were negative for HP infection. Conclusion: This study suggests no association between JCPyV infection and GC or other gastroduodenal diseases. The very low frequency of JCPyV LTag sequences in GC is an important aspect that weakens the hypothesis of the pathogenic role of JCPyV in gastric tumor induction.

show abstract

A Tool to Predict Risk for Gastric Cancer in Patients With Peptic Ulcer Disease on the Basis of a Nationwide Cohort

Cited by 27 publications

References 30 publications

Prediction of the 10‐year probability of gastric cancer occurrence in the Japanese population: the JPHC study cohort II

Prediction of the 10‐year probability of gastric cancer occurrence in the Japanese population: the JPHC study cohort II

Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus–related hepatocellular carcinoma after radiofrequency ablation

No Evidence for an Association between JC Polyomavirus Infection and Gastroduodenal Diseases

Contact Info

Product

Resources

About